Αποτελέσματα Αναζήτησης
1 Φεβ 2024 · Procainamide injection is used to treat irregular heartbeats and to slow an overactive heart. When the heart has a normal heartbeat (rhythm), it will work more efficiently. Procainamide works by slowing the nerve impulses in the heart and reducing the sensitivity of heart tissues.
8 Μαΐ 2023 · Procainamide is given IV or PO with the onset of action in 10 to 30 minutes. The loading dose is of IV procainamide is 10 to 17 mg/kg and administered at a rate of 20 to 50 mg/min. Alternatively, this may be dosed at 100 mg every 5 minutes in adult patients.
Results. A total of 34 consecutive patients (32 male, 94.1%; mean age 74.4 ± 9.7 years) were included in the retrospective analysis. The mean time of procainamide treatment was 12.9 ± 13.7 months (median 9 [2–20] months). The mean dose of procainamide was 1207 ± 487 mg/day.
Procainamide Dosage in ACLS. Procainamide should be used in patients with tachyarrhythmias who are deemed hemodynamically stable. Once the clinician has determined the cardiac rhythm by electrocardiogram, the clinician should begin treatment of the underlying arrhythmia with medication. Here is a dosage chart:
Procainamide is a medication used to manage and treat ventricular arrhythmias, supraventricular arrhythmias, atrial flutter/fibrillation, and Wolf-Parkinson-White syndrome. It is in the antiarrhythmic Agent Class 1A class of medications. This activity reviews the indications, action, and contraindications for procainamide as a valuable agent in ...
First dose: 6 mg rapid IV push; follow with NS flush. Second dose: 12 mg if required. Antiarrhythmic Infusions for Stable Wide-QRS Tachycardia Procainamide IV dose: 20-50 mg/min until arrhythmia suppressed, hypotension ensues, QRS duration increases >50%, or maximum dose 17 mg/kg given.
Study Objectives. Intravenous (IV) procainamide is the first-line recommended medication for cardioversion of recent-onset (<48h) atrial fibrillation and flutter (AF/FL) by the Canadian Cardiovascular Society, while the American Heart Association suggests restricting its use to stable pre-excitation patients with rapid ventricular response.
